Tags

Type your tag names separated by a space and hit enter

Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations.
Inflamm Res. 2001 Mar; 50 Suppl 1:S35-7.IR

Abstract

This paper reviews recent studies that have aimed to establish the relative bioavailability of a new oral formulation of meloxicam, and to evaluate its safety and efficacy in a clinical setting. For the bioavailability study, 16 healthy volunteers were randomised to receive either an oral or a solid formulation of meloxicam 15 mg. The performance of the oral suspension was tested in 286 patients with osteoarthritis who were randomised to receive either formulation at 7.5 mg daily. It was found that the new oral suspension was bioequivalent to the capsules formulation, and was more rapidly absorbed after a single dose. No clinical differences were observed in both efficacy and tolerability parameters with either type of formulation in patients with osteoarthritis. The oral suspension was well accepted by the patients. Hence, the oral suspension provides a useful alternative to solid formulations in the treatment of inflammatory joint diseases and painful musculoskeletal disorders.

Authors+Show Affiliations

Department of Clinical Research, Boehringer Ingelheim Pharma KG, Biberach/Riss, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11339520

Citation

Hanft, G, et al. "Meloxicam Oral Suspension: a Treatment Alternative to Solid Meloxicam Formulations." Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.], vol. 50 Suppl 1, 2001, pp. S35-7.
Hanft G, Türck D, Scheuerer S, et al. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflamm Res. 2001;50 Suppl 1:S35-7.
Hanft, G., Türck, D., Scheuerer, S., & Sigmund, R. (2001). Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.], 50 Suppl 1, S35-7.
Hanft G, et al. Meloxicam Oral Suspension: a Treatment Alternative to Solid Meloxicam Formulations. Inflamm Res. 2001;50 Suppl 1:S35-7. PubMed PMID: 11339520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. AU - Hanft,G, AU - Türck,D, AU - Scheuerer,S, AU - Sigmund,R, PY - 2001/5/8/pubmed PY - 2001/9/14/medline PY - 2001/5/8/entrez SP - S35 EP - 7 JF - Inflammation research : official journal of the European Histamine Research Society ... [et al.] JO - Inflamm. Res. VL - 50 Suppl 1 N2 - This paper reviews recent studies that have aimed to establish the relative bioavailability of a new oral formulation of meloxicam, and to evaluate its safety and efficacy in a clinical setting. For the bioavailability study, 16 healthy volunteers were randomised to receive either an oral or a solid formulation of meloxicam 15 mg. The performance of the oral suspension was tested in 286 patients with osteoarthritis who were randomised to receive either formulation at 7.5 mg daily. It was found that the new oral suspension was bioequivalent to the capsules formulation, and was more rapidly absorbed after a single dose. No clinical differences were observed in both efficacy and tolerability parameters with either type of formulation in patients with osteoarthritis. The oral suspension was well accepted by the patients. Hence, the oral suspension provides a useful alternative to solid formulations in the treatment of inflammatory joint diseases and painful musculoskeletal disorders. SN - 1023-3830 UR - https://www.unboundmedicine.com/medline/citation/11339520/Meloxicam_oral_suspension:_a_treatment_alternative_to_solid_meloxicam_formulations_ L2 - https://dx.doi.org/10.1007/PL00000219 DB - PRIME DP - Unbound Medicine ER -